hydralazine has been researched along with Proteinuria in 42 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " To compare the effects of captopril with more conventional drugs on proteinuria and progression of renal disease, we conducted a prospective, 18-month study in 42 proteinuric (> 500 mg/day) NIDDM and, for comparison, in 31 nondiabetic patients with a variety of renal diseases (NDRD)." | 9.08 | Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases. ( Campese, VM; Huang, TP; Liou, HH, 1995) |
| " To compare the effects of captopril with more conventional drugs on proteinuria and progression of renal disease, we conducted a prospective, 18-month study in 42 proteinuric (> 500 mg/day) NIDDM and, for comparison, in 31 nondiabetic patients with a variety of renal diseases (NDRD)." | 5.08 | Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases. ( Campese, VM; Huang, TP; Liou, HH, 1995) |
| " Moreover, A779 treatment attenuated the reduction in MAP and proteinuria by either captopril (300 mg/L in drinking water) or hydralazine (1." | 3.77 | Angiotensin-(1-7) blockade attenuates captopril- or hydralazine-induced cardiovascular protection in spontaneously hypertensive rats treated with NG-nitro-L-arginine methyl ester. ( Al-Saleh, FM; Benter, IF; Chappell, MC; Diz, DI; Raghupathy, R; Yousif, MH, 2011) |
| " One week after disease induction, animals were randomly assigned to chronic glomerulosclerosis, chronic glomerulosclerosis plus Bay 41-2272 (10 mg/kg body weight/day) or chronic glomerulosclerosis plus hydralazine (15 mg/kg body weight/day)." | 3.73 | Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis. ( Kawachi, H; Krämer, S; Kron, S; Loof, T; Martini, S; Neumayer, HH; Peters, H; Shimizu, F; Wang, Y, 2005) |
| " Stroke-prone spontaneously hypertensive Izumo strain rats were divided into four groups, treated with vehicle, the angiotensin-converting enzyme inhibitor (ACEI) delapril (40 mg/kg per d), the angiotensin receptor antagonist (AT1R-Ant) candesartan cilexetil (1 mg/kg per d), or the vasodilator hydralazine (25 mg/kg per d) from weaning to puberty (3 to 10 wk of age), and then monitored without treatment for 6 mo." | 3.71 | Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. ( Hayashi, M; Nakaya, H; Saruta, T; Sasamura, H, 2001) |
| " The aim of this study was to compare the effects of an equivalent reduction in blood pressure produced by the angiotensin-converting enzyme (ACE) inhibitor spirapril (SPI) and an antihypertensive triple drug combination of hydralazine, reserpine and hydrochlorothiazide (HRH) on kidney function, proteinuria and renal structure in hypertensive diabetic rats." | 3.70 | Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats. ( Armini, L; Bardelli, M; Calci, M; Campanacci, L; Candido, R; Carretta, R; Fabris, B; Fazio, M; Fischetti, F, 1999) |
| " After 10 weeks of treatment with benidipine (1, 3, and 5 mg/kg body weight, p." | 3.70 | Benidipine, a long-acting calcium-channel blocker, prevents the progression to end-stage renal failure in a rat mesangioproliferative glomerulonephritis. ( Kawachi, H; Nakamura, T; Obata, JE; Onitsuka, M; Shimada, Y; Shimizu, F; Yoshida, Y, 2000) |
| "Chronic administration of nitrendipine (N) prevented the development of serious renal damage in Wistar rats with experimental glomerulonephritis." | 3.67 | Comparison of BAY e 5009 (nitrendipine) with dihydralazine in Wistar rats with experimentally induced nephritis. ( Mohácsi, G; Sonkodi, S, 1988) |
| "Hypertension was induced in uninephrectomized control rats (UNx) by subcutaneous implantation of a DOCA pellet plus administration of 1% NaCl in the drinking water (DOCA-salt) for 3 wk." | 1.43 | Pentosan polysulfate preserves renal microvascular P2X1 receptor reactivity and autoregulatory behavior in DOCA-salt hypertensive rats. ( Cha, H; Cook, AK; Guan, Z; Inscho, EW; Pollock, DM; Pollock, JS; Singletary, ST; Van Beusecum, JP, 2016) |
| "Treatment with eplerenone, a selective aldosterone receptor blocker, almost completely prevented podocyte damage and proteinuria, with normalization of elevated reduced nicotinamide-adenine dinucleotide phosphate oxidase activity." | 1.34 | Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. ( Fujita, T; Kawachi, H; Nagase, M; Shibata, S; Yoshida, S, 2007) |
| "Prevention or retardation of diabetic nephropathy (DN) includes anti-hypertensive treatment with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) on the premises that these drugs have an added protective effect beyond their influence on BP." | 1.32 | Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. ( Inagi, R; Ishikawa, N; Koike, H; Kurokawa, K; Miyata, T; Mizuno, M; Nangaku, M; Sada, T; Ueda, Y; van Ypersele de Strihou, C; Yuzawa, H, 2003) |
| "After 20 days of treatment, proteinuria had only increased to 1,272 +/- 135 mg/kg/day, a reduction of 45% compared to the untreated control group (2,300 +/- 346 mg/kg/day; p < 0." | 1.30 | Endothelin-A receptor antagonist combined with hydralazine improves survival and renal function in hypertensive rats. ( Hergenröder, S; Kirchengast, M; Münter, K, 1998) |
| "Enalapril treatment significantly reduced proteinuria (731 +/- 23 vs." | 1.29 | Effects of antihypertensive drugs on the progress of renal failure in hyperlipidemic Imai rats. ( Baba, N; Sakemi, T, 1993) |
| "Captopril was also able to reduce the proteinuria of non-diabetic glomerular origin." | 1.28 | Effects of angiotensin converting enzyme inhibitors on the progression of renal failure and proteinuria in humans. ( Alcazar, JM; Gutierrez-Millet, V; Oliet, A; Praga, M; Rodicio, JL; Ruilope, LM, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (35.71) | 18.7374 |
| 1990's | 9 (21.43) | 18.2507 |
| 2000's | 9 (21.43) | 29.6817 |
| 2010's | 8 (19.05) | 24.3611 |
| 2020's | 1 (2.38) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, K | 2 |
| Shimokawa, T | 1 |
| Yamagata, M | 1 |
| Yoneda, K | 1 |
| Alexander, JM | 1 |
| Wilson, KL | 1 |
| Arruda-Junior, DF | 1 |
| Virgulino, SG | 1 |
| Girardi, AC | 1 |
| Wang, Y | 2 |
| Xie, BQ | 1 |
| Gao, WH | 1 |
| Yan, DY | 1 |
| Zheng, WL | 1 |
| Lv, YB | 1 |
| Cao, YM | 1 |
| Hu, JW | 1 |
| Yuan, ZY | 1 |
| Mu, JJ | 1 |
| Guan, Z | 1 |
| Singletary, ST | 1 |
| Cha, H | 1 |
| Van Beusecum, JP | 1 |
| Cook, AK | 1 |
| Pollock, JS | 1 |
| Pollock, DM | 1 |
| Inscho, EW | 1 |
| Benter, IF | 1 |
| Yousif, MH | 1 |
| Al-Saleh, FM | 1 |
| Raghupathy, R | 1 |
| Chappell, MC | 1 |
| Diz, DI | 1 |
| Azegami, T | 1 |
| Sasamura, H | 2 |
| Itoh, H | 1 |
| Ogawa, Y | 1 |
| Mukoyama, M | 1 |
| Yokoi, H | 1 |
| Kasahara, M | 1 |
| Mori, K | 1 |
| Kato, Y | 1 |
| Kuwabara, T | 1 |
| Imamaki, H | 1 |
| Kawanishi, T | 1 |
| Koga, K | 1 |
| Ishii, A | 1 |
| Tokudome, T | 1 |
| Kishimoto, I | 1 |
| Sugawara, A | 1 |
| Nakao, K | 1 |
| Villa, L | 1 |
| Boor, P | 1 |
| Konieczny, A | 1 |
| Kunter, U | 1 |
| van Roeyen, CR | 1 |
| Denecke, B | 1 |
| Gan, L | 1 |
| Neusser, MA | 1 |
| Cohen, CD | 1 |
| Eitner, F | 1 |
| Scholl, T | 1 |
| Ostendorf, T | 1 |
| Floege, J | 1 |
| Nangaku, M | 1 |
| Miyata, T | 1 |
| Sada, T | 1 |
| Mizuno, M | 1 |
| Inagi, R | 1 |
| Ueda, Y | 1 |
| Ishikawa, N | 1 |
| Yuzawa, H | 1 |
| Koike, H | 1 |
| van Ypersele de Strihou, C | 1 |
| Kurokawa, K | 1 |
| SARLES, HE | 1 |
| HERRING, ME | 1 |
| WATSON, TF | 1 |
| GREGORY, RL | 1 |
| REMMERS, AR | 1 |
| Soto, K | 1 |
| Gómez-Garre, D | 1 |
| Largo, R | 1 |
| Gallego-Delgado, J | 1 |
| Tejera, N | 1 |
| Catalán, MP | 1 |
| Ortiz, A | 1 |
| Plaza, JJ | 1 |
| Alonso, C | 1 |
| Egido, J | 1 |
| Cachat, F | 1 |
| Bogaru, A | 1 |
| Micheli, JL | 1 |
| Lepori, D | 1 |
| Guignard, JP | 1 |
| Krämer, S | 1 |
| Loof, T | 1 |
| Martini, S | 1 |
| Kron, S | 1 |
| Kawachi, H | 4 |
| Shimizu, F | 3 |
| Neumayer, HH | 1 |
| Peters, H | 1 |
| Nagase, M | 2 |
| Shibata, S | 2 |
| Yoshida, S | 2 |
| Nagase, T | 1 |
| Gotoda, T | 1 |
| Fujita, T | 2 |
| Moyer, JH | 1 |
| Feld, LG | 1 |
| Van Liew, JB | 1 |
| Brentjens, JR | 1 |
| Boylan, JW | 1 |
| Liou, HH | 1 |
| Huang, TP | 1 |
| Campese, VM | 1 |
| Sakemi, T | 1 |
| Baba, N | 1 |
| Reisin, E | 1 |
| Azar, S | 1 |
| DeBoisblanc, BP | 1 |
| Guzman, MA | 1 |
| Lohmann, T | 1 |
| Kohara, K | 1 |
| Mikami, H | 1 |
| Okuda, N | 1 |
| Higaki, J | 1 |
| Ogihara, T | 1 |
| Tsuboi, Y | 1 |
| Shankland, SJ | 1 |
| Grande, JP | 1 |
| Walker, HJ | 1 |
| Johnson, RJ | 1 |
| Dousa, TP | 1 |
| Münter, K | 1 |
| Hergenröder, S | 1 |
| Kirchengast, M | 1 |
| Nakamura, T | 2 |
| Obata, J | 1 |
| Kimura, H | 1 |
| Ohno, S | 1 |
| Yoshida, Y | 2 |
| Fabris, B | 1 |
| Candido, R | 1 |
| Armini, L | 1 |
| Fischetti, F | 1 |
| Calci, M | 1 |
| Bardelli, M | 1 |
| Fazio, M | 1 |
| Campanacci, L | 1 |
| Carretta, R | 1 |
| Aizawa, T | 1 |
| Ishizaka, N | 1 |
| Taguchi, Ji | 1 |
| Nagai, R | 1 |
| Mori, I | 1 |
| Tang, SS | 1 |
| Ingelfinger, JR | 1 |
| Ohno, M | 1 |
| Obata, JE | 1 |
| Onitsuka, M | 1 |
| Shimada, Y | 1 |
| Nakaya, H | 1 |
| Hayashi, M | 1 |
| Saruta, T | 1 |
| Mogensen, CE | 1 |
| Rodicio, JL | 2 |
| Alcazar, JM | 2 |
| Ruilope, LM | 2 |
| Mohácsi, G | 1 |
| Sonkodi, S | 1 |
| Derham, RJ | 1 |
| Hawkins, DF | 1 |
| De Vries, LS | 1 |
| Aber, VR | 1 |
| Elder, MG | 1 |
| Praga, M | 1 |
| Oliet, A | 1 |
| Gutierrez-Millet, V | 1 |
| Anderson, S | 1 |
| Rennke, HG | 1 |
| Brenner, BM | 1 |
| Wilhelmsen, L | 1 |
| Berglund, G | 1 |
| Werkö, L | 1 |
| Groover, ME | 1 |
| Fulghum, JE | 1 |
| Simpson, WG | 1 |
| Wilber, JA | 1 |
| Haller, J | 1 |
| Vaidya, RA | 1 |
| Vaidya, AB | 1 |
| Van Woert, MH | 1 |
| Kase, NG | 1 |
| Ragni, N | 1 |
| Cadenelli, GP | 1 |
| Harley, JM | 1 |
2 reviews available for hydralazine and Proteinuria
| Article | Year |
|---|---|
Hypertensive emergencies of pregnancy.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Creatine; Diuretics; Emergency Medicine; Female; | 2013 |
Drug systems approach to hypertension.
Topics: Captopril; Clonidine; Drug Combinations; Drug Therapy, Combination; Guanethidine; Humans; Hydralazin | 1984 |
2 trials available for hydralazine and Proteinuria
| Article | Year |
|---|---|
Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; Diabetic Ne | 1995 |
Influence of converting enzyme inhibition on glomerular filtration rate and proteinuria.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Female; Furos | 1990 |
38 other studies available for hydralazine and Proteinuria
| Article | Year |
|---|---|
Inhibition of α
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Blister; Disease Models, Animal; Disease Progressi | 2021 |
Reduced tubular proteinuria in hypertensive rats treated with losartan is associated with higher renal cortical megalin expression.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Glomerular Filtration Barrier; Hydralazine; Kidney | 2014 |
Effects of Renin-Angiotensin System Inhibitors on Renal Expression of Renalase in Sprague-Dawley Rats Fed With High Salt Diet.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr | 2015 |
Pentosan polysulfate preserves renal microvascular P2X1 receptor reactivity and autoregulatory behavior in DOCA-salt hypertensive rats.
Topics: Adenosine Triphosphate; Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Arterioles; Bloo | 2016 |
Angiotensin-(1-7) blockade attenuates captopril- or hydralazine-induced cardiovascular protection in spontaneously hypertensive rats treated with NG-nitro-L-arginine methyl ester.
Topics: Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Brai | 2011 |
Vaccination against the angiotensin type 1 receptor for the prevention of L-NAME-induced nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Enzyme Inhibit | 2012 |
Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury.
Topics: Acute Kidney Injury; Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Cells, Cultured; | 2012 |
Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Benzimidazoles; | 2013 |
Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.
Topics: Animals; Antihypertensive Agents; Arginine; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mel | 2003 |
THE NEPHROTIC SYNDROME DUE TO PRE-ECLAMPTIC NEPHROPATHY; REPORT OF A CASE.
Topics: Blood Pressure; Blood Pressure Determination; Drug Therapy; Female; Humans; Hydralazine; Kidney Dise | 1964 |
Tight blood pressure control decreases apoptosis during renal damage.
Topics: Animals; Antihypertensive Agents; Apoptosis; Blood Pressure; Cell Division; Drug Therapy, Combinatio | 2004 |
Severe hypertension and massive proteinuria in a newborn with renal artery stenosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aorta, Abdominal; Blood Pressure; | 2004 |
Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
Topics: Animals; Biomarkers; Blood Pressure; Body Weight; Chronic Disease; Disease Progression; Eating; Enzy | 2005 |
Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker.
Topics: Animals; Apoptosis; Biomarkers; Blood Pressure; Eplerenone; Fibrosis; Glomerulosclerosis, Focal Segm | 2006 |
Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.
Topics: Aldosterone; Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Cells, Cultured; Cyclic | 2007 |
Renal lesions and proteinuria in the spontaneously hypertensive rat made normotensive by treatment.
Topics: Age Factors; Animals; Arteriosclerosis; Blood Pressure; Chlorothiazide; Hydralazine; Hypertension; K | 1981 |
Effects of antihypertensive drugs on the progress of renal failure in hyperlipidemic Imai rats.
Topics: Animals; Antihypertensive Agents; Cholesterol; Drug Therapy, Combination; Enalapril; Hydralazine; Hy | 1993 |
Low calorie unrestricted protein diet attenuates renal injury in hypertensive rats.
Topics: Animals; Blood Pressure; Diet, Reducing; Dietary Proteins; Energy Intake; Hydralazine; Kidney; Kidne | 1993 |
Angiotensin blockade and the progression of renal damage in the spontaneously hypertensive rat.
Topics: Albuminuria; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzi | 1993 |
Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Actins; Animals; Blood Pressure; Calcium-Calmodulin-Dependent P | 1996 |
Endothelin-A receptor antagonist combined with hydralazine improves survival and renal function in hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Endothelin Receptor Antagonists; Hydralazine; Hype | 1998 |
Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1999 |
Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Diabetic | 1999 |
Heme oxygenase-1 is upregulated in the kidney of angiotensin II-induced hypertensive rats : possible role in renoprotection.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cell Line, Transformed; Disease Mo | 2000 |
Benidipine, a long-acting calcium-channel blocker, prevents the progression to end-stage renal failure in a rat mesangioproliferative glomerulonephritis.
Topics: Actins; Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Creatinine; Dihydropyridines | 2000 |
Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angioten | 2001 |
Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment.
Topics: Adolescent; Adult; Albuminuria; Diabetic Nephropathies; Furosemide; Glomerular Filtration Rate; Huma | 1976 |
Comparison of BAY e 5009 (nitrendipine) with dihydralazine in Wistar rats with experimentally induced nephritis.
Topics: Animals; Antibodies; Basement Membrane; Blood Pressure; Dihydralazine; Glomerulonephritis; Hydralazi | 1988 |
Outcome of pregnancies complicated by severe hypertension and delivered before 34 weeks; stepwise logistic regression analysis of prognostic factors.
Topics: Adult; Birth Weight; Cerebral Hemorrhage; Cesarean Section; Female; Fetal Growth Retardation; Gestat | 1989 |
Effects of angiotensin converting enzyme inhibitors on the progression of renal failure and proteinuria in humans.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Female; Furos | 1989 |
Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Enalapril; Glomerular Filtration Rate; Hydralazin | 1986 |
Prevalence and management of hypertension in a general population sample of Swedish men.
Topics: Adrenergic beta-Antagonists; Adult; Bacteriuria; Blood Pressure; Costs and Cost Analysis; Creatinine | 1973 |
Arterial hypertension--northwest Florida public health survey. II. Diagnosis and treatment.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Urea Nitrogen; Chlorothiazide; Diuretics | 1974 |
The management of hypertension during pregnancy.
Topics: Adolescent; Adult; Blood Pressure; Clinical Laboratory Techniques; Diagnosis, Differential; Dihydrox | 1972 |
[Therapy of EPH gestosis].
Topics: Chlorthalidone; Diazepam; Diet Therapy; Eclampsia; Edema; Female; Furosemide; Guanethidine; Humans; | 1973 |
Galactorrhea and Parkinson-like syndrome: an adverse effect of alpha-methyldopa.
Topics: Adolescent; Amenorrhea; Female; Glomerulonephritis; Humans; Hydralazine; Hypertension; Kidney Transp | 1970 |
[On a new hypotensive pharmacological association in pregnancy with hypertension].
Topics: Adult; Antihypertensive Agents; Blood Pressure; Carbamates; Creatinine; Electrolytes; Female; Humans | 1971 |
Essential hypertension complicating pregnancy: Factors affecting the fetal mortality.
Topics: Adult; Female; Fetal Death; Humans; Hydralazine; Hypertension; Middle Aged; Pregnancy; Pregnancy Com | 1966 |